Metagenomi price target lowered to $7 from $14 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Metagenomi (MGX) to $7 from $14 and keeps a Buy rating on the shares following the Q4 report. Macroeconomic uncertainties weigh on the genetic medicines field, with reflection in development-stage gene editing stocks, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue